Animal and Human Studies with Oral Mitomycin C(6): A Preliminary Report
Mitomycin C, a product of Streptomyces caespetosus, is an antineoplastic antibiotic marketed for intravenous usage (1). Extravasation outside the vein at the site of the injection results in painful necrosis of the surrounding tissue, and daily intravenous injections are a difficult method to use when continuous low dose therapy is desired. Consideration was given to the development of an oral form of Mitomycin C. This paper reports results from our initial animal and human trials. We later learned that oral Mitomycin C has been used clinically in Japan.
KeywordsNone None Leukaemic Cell Bone Marrow Toxicity Variable Toxicity Haematologic Toxicity
Unable to display preview. Download preview PDF.
- 1.Carter, S.K. (1968), Mitomycin C (NSC-26980)-Clinical Brochure Cancer Chemotherapy Reports, Part 3, Vol. 1., 99–104.Google Scholar
- 3.Whittington, R.M. and Close, H.P. (1970). Clinical Experience with Mitomycin C. (NSC-26980) — Cancer Chemotherapy Reports, Part 1, Vol. 51., 195–198, No. 3.Google Scholar